Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890161608> ?p ?o ?g. }
- W2890161608 endingPage "2087" @default.
- W2890161608 startingPage "2079" @default.
- W2890161608 abstract "Daratumumab, a CD38 human monoclonal antibody, demonstrated significant clinical activity in combination with bortezomib and dexamethasone versus bortezomib and dexamethasone alone in the primary analysis of CASTOR, a phase 3 study in relapsed and/or refractory multiple myeloma. A post hoc analysis based on treatment history and longer follow up is presented. After 19.4 (range: 0-27.7) months of median follow up, daratumumab plus bortezomib and dexamethasone prolonged progression-free survival (median: 16.7 versus 7.1 months; hazard ratio, 0.31; 95% confidence interval, 0.24-0.39; P2.5-fold higher with daratumumab across subgroups. The safety profile of daratumumab plus bortezomib and dexamethasone remained consistent with longer follow up. Daratumumab plus bortezomib and dexamethasone demonstrated significant clinical activity across clinically relevant subgroups and provided the greatest benefit to patients treated at first relapse. Trial registration: clinicaltrials.gov identifier: 02136134." @default.
- W2890161608 created "2018-09-27" @default.
- W2890161608 creator A5000193525 @default.
- W2890161608 creator A5002073335 @default.
- W2890161608 creator A5002718187 @default.
- W2890161608 creator A5002972322 @default.
- W2890161608 creator A5003294000 @default.
- W2890161608 creator A5003652233 @default.
- W2890161608 creator A5004677468 @default.
- W2890161608 creator A5004823958 @default.
- W2890161608 creator A5009117622 @default.
- W2890161608 creator A5010286156 @default.
- W2890161608 creator A5010388094 @default.
- W2890161608 creator A5011533368 @default.
- W2890161608 creator A5012187284 @default.
- W2890161608 creator A5015733850 @default.
- W2890161608 creator A5022520524 @default.
- W2890161608 creator A5022522496 @default.
- W2890161608 creator A5023066145 @default.
- W2890161608 creator A5023084660 @default.
- W2890161608 creator A5025218236 @default.
- W2890161608 creator A5030524608 @default.
- W2890161608 creator A5031344736 @default.
- W2890161608 creator A5033439690 @default.
- W2890161608 creator A5035403729 @default.
- W2890161608 creator A5039833411 @default.
- W2890161608 creator A5041718881 @default.
- W2890161608 creator A5053560614 @default.
- W2890161608 creator A5054343933 @default.
- W2890161608 creator A5056839401 @default.
- W2890161608 creator A5058666996 @default.
- W2890161608 creator A5065915270 @default.
- W2890161608 creator A5066247828 @default.
- W2890161608 creator A5067860129 @default.
- W2890161608 creator A5068837815 @default.
- W2890161608 creator A5071926851 @default.
- W2890161608 creator A5074020738 @default.
- W2890161608 creator A5086077649 @default.
- W2890161608 creator A5091396091 @default.
- W2890161608 date "2018-09-20" @default.
- W2890161608 modified "2023-10-18" @default.
- W2890161608 title "Daratumumab plus bortezomib and dexamethasone <i>versus</i> bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR" @default.
- W2890161608 cites W1585625390 @default.
- W2890161608 cites W1902692042 @default.
- W2890161608 cites W1985864219 @default.
- W2890161608 cites W1994895013 @default.
- W2890161608 cites W2003734726 @default.
- W2890161608 cites W2004351861 @default.
- W2890161608 cites W2037050131 @default.
- W2890161608 cites W2044436186 @default.
- W2890161608 cites W2086595383 @default.
- W2890161608 cites W2087843841 @default.
- W2890161608 cites W2091773528 @default.
- W2890161608 cites W2096367061 @default.
- W2890161608 cites W2116767586 @default.
- W2890161608 cites W2136541422 @default.
- W2890161608 cites W2141105112 @default.
- W2890161608 cites W2141502099 @default.
- W2890161608 cites W2171757275 @default.
- W2890161608 cites W2193716145 @default.
- W2890161608 cites W2201190784 @default.
- W2890161608 cites W2216707999 @default.
- W2890161608 cites W2229483068 @default.
- W2890161608 cites W2253038466 @default.
- W2890161608 cites W2336872381 @default.
- W2890161608 cites W2343386476 @default.
- W2890161608 cites W2400276917 @default.
- W2890161608 cites W2424457748 @default.
- W2890161608 cites W2443548094 @default.
- W2890161608 cites W2486629951 @default.
- W2890161608 cites W2512106959 @default.
- W2890161608 cites W2528329272 @default.
- W2890161608 cites W2557804801 @default.
- W2890161608 cites W2576721970 @default.
- W2890161608 cites W2592673843 @default.
- W2890161608 cites W2688500010 @default.
- W2890161608 cites W2749746182 @default.
- W2890161608 doi "https://doi.org/10.3324/haematol.2018.194118" @default.
- W2890161608 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6269293" @default.
- W2890161608 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30237264" @default.
- W2890161608 hasPublicationYear "2018" @default.
- W2890161608 type Work @default.
- W2890161608 sameAs 2890161608 @default.
- W2890161608 citedByCount "218" @default.
- W2890161608 countsByYear W28901616082018 @default.
- W2890161608 countsByYear W28901616082019 @default.
- W2890161608 countsByYear W28901616082020 @default.
- W2890161608 countsByYear W28901616082021 @default.
- W2890161608 countsByYear W28901616082022 @default.
- W2890161608 countsByYear W28901616082023 @default.
- W2890161608 crossrefType "journal-article" @default.
- W2890161608 hasAuthorship W2890161608A5000193525 @default.
- W2890161608 hasAuthorship W2890161608A5002073335 @default.
- W2890161608 hasAuthorship W2890161608A5002718187 @default.
- W2890161608 hasAuthorship W2890161608A5002972322 @default.
- W2890161608 hasAuthorship W2890161608A5003294000 @default.
- W2890161608 hasAuthorship W2890161608A5003652233 @default.
- W2890161608 hasAuthorship W2890161608A5004677468 @default.